Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wim Robberecht

Showing results (91-100 of 182) with videos related to

Pageof 19
Sort By:
Human Mutation|July 12, 2007
Genetic variant in the HSPB1 promoter region impairs the HSP27 stress responseInes Dierick, Joy Irobi, Sophie Janssens, et al.
Human Molecular Genetics|October 16, 2012
Novel COL4A1 mutations cause cerebral small vessel disease by haploinsufficiencyRobin Lemmens, Alessandra Maugeri, Hans W M Niessen, et al.
Human Molecular Genetics|February 21, 2012
Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosisSarah Herdewyn, Hui Zhao, Matthieu Moisse, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 27, 2007
Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshopAlbert C Ludolph, Caterina Bendotti, Eran Blaugrund, et al.
Journal of the Peripheral Nervous System : JPNS|June 21, 2013
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)Jean-Marc Léger, Jan L De Bleecker, Claudia Sommer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 1, 2014
Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosisStefan Lehnert, Julia Costa, Mamede de Carvalho, et al.
Journal of the Peripheral Nervous System : JPNS|June 9, 2017
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trialIngemar S J Merkies, John-Philip Lawo, Jonathan M Edelman, et al.
Neurobiology of Disease|September 25, 2002
CuZn-superoxide dismutase in D90A heterozygotes from recessive and dominant ALS pedigreesP Andreas Jonsson, Asa Bäckstrand, Peter M Andersen, et al.
Annals of Neurology|March 17, 2009
Serum biomarker for progranulin-associated frontotemporal lobar degenerationKristel Sleegers, Nathalie Brouwers, Philip Van Damme, et al.
Human Molecular Genetics|June 12, 2010
Mutant HSPB8 causes motor neuron-specific neurite degenerationJoy Irobi, Leonardo Almeida-Souza, Bob Asselbergh, et al.
Pageof 19

Showing results (91-100 of 182) with videos related to

Sort By:
Pageof 19
Human Mutation|July 12, 2007
Genetic variant in the HSPB1 promoter region impairs the HSP27 stress responseInes Dierick, Joy Irobi, Sophie Janssens, et al.
Human Molecular Genetics|October 16, 2012
Novel COL4A1 mutations cause cerebral small vessel disease by haploinsufficiencyRobin Lemmens, Alessandra Maugeri, Hans W M Niessen, et al.
Human Molecular Genetics|February 21, 2012
Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosisSarah Herdewyn, Hui Zhao, Matthieu Moisse, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|July 27, 2007
Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshopAlbert C Ludolph, Caterina Bendotti, Eran Blaugrund, et al.
Journal of the Peripheral Nervous System : JPNS|June 21, 2013
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)Jean-Marc Léger, Jan L De Bleecker, Claudia Sommer, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 1, 2014
Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosisStefan Lehnert, Julia Costa, Mamede de Carvalho, et al.
Journal of the Peripheral Nervous System : JPNS|June 9, 2017
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trialIngemar S J Merkies, John-Philip Lawo, Jonathan M Edelman, et al.
Neurobiology of Disease|September 25, 2002
CuZn-superoxide dismutase in D90A heterozygotes from recessive and dominant ALS pedigreesP Andreas Jonsson, Asa Bäckstrand, Peter M Andersen, et al.
Annals of Neurology|March 17, 2009
Serum biomarker for progranulin-associated frontotemporal lobar degenerationKristel Sleegers, Nathalie Brouwers, Philip Van Damme, et al.
Human Molecular Genetics|June 12, 2010
Mutant HSPB8 causes motor neuron-specific neurite degenerationJoy Irobi, Leonardo Almeida-Souza, Bob Asselbergh, et al.
Pageof 19